Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TALPHERA, INC. Director's Dealing 2019

Feb 7, 2019

35181_dirs_2019-02-07_20c6e7b7-af7d-4c5c-989a-f76d063a626e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2018-12-31

Reporting Person: HOFFMAN STEPHEN J (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-07-24 Stock Option (Right to Buy) $10.22 A 15000 Acquired 2024-07-23 Common Stock (15000) Direct
2015-06-23 Stock Option (Right to Buy) $4.08 A 15000 Acquired 2025-06-22 Common Stock (15000) Direct
2016-06-21 Stock Option (Right to Buy) $2.87 A 15000 Acquired 2026-06-20 Common Stock (15000) Direct
2017-06-15 Stock Option (Right to Buy) $2.30 A 15000 Acquired 2027-06-14 Common Stock (15000) Direct
2018-06-14 Stock Option (Right to Buy) $4.125 A 15000 Acquired 2028-06-14 Common Stock (15000) Direct

Footnotes

F1: Issued pursuant to the 2011 Equity Incentive Plan.

F2: Transactions were previously reported on Form 4, but were inadvertently filed using incorrect CIK and CCC numbers which resulted in the reports appearing incorrectly as a report of a person different from the Reporting Person. This Form 5 is being filed to identify correctly these past transactions as the Reporting Person's transactions and to reflect accurately the Reporting Person's beneficial ownership holdings in the Issuer.

F3: Fully vested.

F4: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors.

F5: 100% Acceleration upon Change of Control.